Korro Bio, Inc. Cash Flow Statement
KRRO|6 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Korro Bio, Inc. used $60M in operating cash flow and negative free cash flow of $78M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Net Income | -$83.6M | -$81.2M | -$84.7M | -$26.5M | -$18.7M | -$20.2M |
| Depreciation & Amortization | $3.6M | $3.6M | $2.8M | $1.1M | $813.0K | $531.0K |
| Operating Cash Flow | -$60.1M | -$67.3M | -$76.1M | -$45.2M | $34.2M | -$14.6M |
| Capital Expenditures | $17.9M | $7.8M | $2.9M | $6.7M | $1.1M | $1.9M |
| Free Cash Flow | -$78.0M | -$75.1M | -$79.0M | -$51.9M | $33.2M | -$16.5M |
| FCF Margin | -3433.6% | - | -561.4% | -140.2% | 114.5% | -68.0% |